and in 2008-2011 (DEGS1). 11 Both surveys consist of a nationwide 2-stage clustered sample from local population registers of adults aged 18-79 years (7,124 GNHIES98 participants from 120 communities and 7,988 DEGS1 participants from 180 communities). All GNHIES98 participants were invited to re-participate in DEGS1 (response rate 64%, n = 3,795). An additional cross-sectional sample of 4, 193 first-time participants (response rate 42%) were recruited for DEGS1 based on the same sampling design. Both GNHIES98 and DEGS1 include largely identical survey methods as well as measurement protocols (self-administered questionnaires, computer-assisted personal interviews conducted by a study physician, medical examinations, physiological measurements, and the collection of blood and urine samples) making possible the estimation of time trends. 11, 12 Participants provided written informed consent prior to interview and examination in both studies.
Measurements and definitions.
Three BP measurements were taken in both surveys at the right arm at 3-minute intervals after a non-strenuous part of the examination and an additional 5-minute rest. Participants sat on a heightadjustable chair, back supported, arm lying on a table at heart level, feet on the floor and legs uncrossed. A standard mercury sphygmomanometer (Erkameter 3000; Erka, Bad Tölz, Germany) was used in GNHIES98 and an automated oscillometric device (Datascope Accutorr Plus, Mahwah, NJ) in DEGS1. Three different cuff sizes were used in each study. 13 GNHIES98 BP data were calibrated for comparison with DEGS1 data based on a validation study in order to account for cuff and device differences. 13 The second and third measurements were averaged.
Antihypertensive medication intake was recorded during computer-assisted personal interviews; 7,099 adults have participated in the medication interview from GNHIES98 and 7,091 from DEGS1. Participants were requested to bring all original medication packages they had used in the previous 7 days and all Anatomical Therapeutic Chemical (ATC) codes were documented. 14 Hypertension was defined as mean SBP ≥140 mm Hg, or mean DBP ≥90 mm Hg, or the use of antihypertensives (ATC codes: C02 antihypertensives, C03 diuretics, C07 beta-blockers, C08 CCB or C09 ACE inhibitors, and ARB). However, as the indication for taking these drugs may be other than hypertension, antihypertensive medication was only used for defining prevalent and treated hypertension if the participants reported having hypertension.
For the analysis of hypertension treatment and control 7 classes of antihypertensives (diuretics, thiazide-diuretics, beta-blockers, CCB, ACE inhibitors, ARB, and antihypertensive) based on detailed ATC codes were examined (Supplementary Data online). Monotherapy was defined as the use of only one antihypertensive agent, and polytherapy (combination therapy) was defined as the use of >1 antihypertensive agent. Single-pill antihypertensive combination users were considered to be receiving polytherapy. If a person used antihypertensive medication containing more than 1 active ingredient the person was counted once within each of the antihypertensive classes.
In contrast to previous analyses, 10 10 participants with imprecise self-reported medication (as compared to those who brought medication packages) were not counted as treated. Therefore, estimates of treatment and control may differ by less than 1% compared to previous reports. Control was defined as: SBP < 140 mm Hg and DBP < 90 mm Hg in treated adults with hypertension.
We investigated a range of self-reported participants' characteristics for associations with antihypertensive use and BP control. Socio-demographic characteristics included age, gender, socioeconomic status based on income, education, and occupation 15 ; municipality size classified into the categories rural (<5,000 inhabitants), small town (5,000 to <20,000 inhabitants), medium-sized town (20,000 to <100,000 inhabitants), and city (>100,000 inhabitants); the 16 states in Germany were grouped into 5 regions North-West (SchleswigHolstein, Hamburg, Niedersachsen, Bremen), NorthEast (Mecklenburg-Vorpommern, Brandenburg, Berlin), Central-West (Nordrhein-Westfalen, Hessen, RheinlandPfalz, Saarland), Central-East (Sachsen-Anhalt, Sachsen, Thüringen), and South (Bayern, Baden-Württemberg); and health insurance classified into statutory, private, and other.
A medical interview covered health conditions and previous medical diagnoses such as diabetes mellitus (excluding ever having diabetes during pregnancy), coronary heart disease (CHD), or stroke. Alcohol consumption was measured using the validated German-language version 16 of the 3 questions Alcohol Use Disorders Identification Test (AUDIT-C) as a brief screening test for heavy drinking and/or active alcohol abuse or dependence. Women and men with more than 4 and 5 points respectively on the 12-point scale were classified as high-risk alcohol drinkers. 17, 18 Smoking status was categorized as daily or occasional smoker, ex-smoker, and never-smoker. Physical activity was categorized as no physical activity, up to 2 hours/week, 2-4 hours/week, and more than 4 hours/week. 19 
Statistical analysis
This analysis is restricted to adults with hypertension according to the above definition (2,635 in DEGS1 and 2,037 in GNHIES98). To examine the prevalence of antihypertensive use both cross-sectional and trend analyses were conducted using a weighting factor that corrects for deviations in the sample from the population structure with regard to age, sex, region of residence, nationality, as well as municipality size and educational level reflecting the German population as of 31 December 2010.
DEGS1 weights of former GNHIES98 participants additionally included adjustment for re-participation probability. 11 Descriptive statistics were used to examine characteristics of the study population. Antihypertensive users were then stratified by socio-demographic and health characteristics. To examine relationships between antihypertensive use, BP control, and socio-demographic and health characteristics, unadjusted and adjusted odds ratios (OR) and 95% confidence interval (95% CI) were determined using bivariate and multivariable logistic regression models. Interactions of sex with all other independent variables were tested for medication use and BP control. The SPSS-20 Complex Samples method was used in the analysis to account for the weighting and the clustering due to the 2-stage sampling procedure. Group differences were considered statistically significant for P-values less than 0.05.
RESULTS
The prevalence of hypertension in adults (18- Among treated in 1998, 43.8% used monotherapy and 56.2% polytherapy, while in 2008-2011 the proportion of monotherapy had decreased to 32.9% and polytherapy had increased to 67.1%. The proportion of polytherapy was similar in men and women in both surveys ( Table 1) .
The most commonly used antihypertensive classes over this 10-year period were beta-blockers (39% in 1998 and 54% in 2008-2011) and diuretics (43% in 1998 and 48% in 2008-2011) ( Figure 1 ). The greatest increase in the prevalence of antihypertensive use was observed for thiazide-diuretics with a rise of 24 percentage points (from 15% in 1998 to 39% in 2008-2011, P = 0.000) and for ARB with a rise of 24 percentage points over this 10-year period (from 6% in 1998 to 30% in 2008-2011, P = 0.000). On the other hand, a significant decrease over time was observed for CCB and for antihypertensives of the ATC-code C02.
The overall BP control rate among adults with treated hypertension has significantly increased from 41.5% (95% CI 37.4-45.9) in 1998 to 71.5% (95% CI 68.5-74.3) in 2008-2011 (P = 0.000). This increase can be observed among almost all groups ( Figure 1 ). Even though CCB became less frequently used, the control rate among this group has also increased. The greatest improvement in control was found for the ARB group with a control rate among treated of 35.6% (95% CI 23.7-49.7) in 1998 and of 75.7% (95% CI 71.7-79.4) in 2008-2011 (P = 0.000).
Among those using only monotherapy, the control rate has significantly increased from 38.7% to 67.7%, and among those using polytherapy from 43.8% to 73.3%. In almost all stratified groups a statistically significant upward trend in BP control among treated was observed (Table 2) . Even though BP control in patients with diabetes treated with monotherapy has improved from 36% to 55%, the comparison has limited power and was marginally statistically significant.
The most frequently used antihypertensive agents changed over time ( Figure 2 ). The largest changes were observed among ACE inhibitors, CCB and beta-blockers. Among treated in 1998, captopril was used by 12.3% but only by 1.1% in 2008-2011 (P = 0.000). Conversely, ramipril was used only by 1.8% in 1998 but by 19.0% in 2008-2011, being currently together with metoprolol (20.3%) the most commonly used monotherapy agents for hypertension in Germany. Among the CCB group, amlodipine use has significantly increased from 5.0% to 12.6% (P = 0.000), whereas nifedipine use has significantly decreased from 10.4% to 0.5% (P = 0.000). Regarding polytherapy, the most commonly used combination in 1998 was hydrochlorothiazide and potassium-sparing agents (8.9%; 95% CI 7.0-11.3) and in 2008-2011 ramipril and hydrochlorothiazide (6.7%; 95% CI 5.5-8.0) (data not shown in the figure).
Antihypertensive use was higher in women than in men (prevalence of use 78.7% vs. 65.1%) (univariate OR = 1.98; 95% CI 1.54-2.55; P = 0.000). In multivariable analysis, being a woman, increasing age, having statutory health insurance, diabetes, CHD, stroke, and obesity were associated with more antihypertensive use ( Table 3) .
BP control was somewhat higher in polytherapy than in monotherapy users (73.3% vs. 67.7%; univariate OR = 1.31; 95% CI 1.03-1.68; P = 0.031). However, this difference was not significant any more after adjusting for other variables that can influence BP control (Table 4 ). This analysis included socio-demographic variables (sex, age, an interaction term for age with sex, socioeconomic status, and region); lifestyle factors that can influence BP control such as physical exercise and alcohol drinking; antihypertensive therapy type (mono-vs. polytherapy), and cardiovascular risk indicators that may influence both therapy and health behavior such as previous CHD or stroke, diabetes, obesity, and smoking. The association of age and sex with control was driven by the high control rate in younger women (85% control among treated women aged 18-54 compared to control rates of 64%-72% in younger men and in older men and women). Age was a predictor of control only in women (younger women had better control than older women, OR 2.33; 95% CI 1.37-3.96) but not in men. Gender on the other hand was associated with control only in the younger age group (in adults, 18-to 54-year-old women had better control than men, OR 3.18 (95% CI 1.58-6.45)) but not in the older group. Further interactions between sex and region and sex and socioeconomic status were tested but were not significant. Hypertensive adults having diabetes or a high-risk alcohol drinking had a poorer BP control compared to hypertensive adults without these factors. On the other hand, having CHD or stroke as comorbidity was associated with a better control.
DISCUSSION
This study shows a 30% increase in antihypertensive use over a 10-year period among hypertensive adults in Germany (from 54% to 72%) and a 43% increase in the control rate among treated in the same period (from 42% to 72%). Even though the prevalence of hypertension in the adult population of Germany remains almost unchanged (32%), the age-and sex-standardized mean of SBP and DBP has dropped by 5 mm Hg in the overall population and by 14 mm Hg SBP and 10 mm Hg DBP between the crosssectional samples with treated hypertension. 10 These findings suggest that increased and improved antihypertensive use is a main contributor to the decrease of BP observed in Germany in the last decade particularly among the middle and older age groups of adults. In the young group (aged 18-44 years) the treatment proportion has not much increased and hypertensive adults remain untreated in two thirds of cases. Special attention may be necessary for subgroups that have poorer control among treated despite increased cardiovascular risk, for example, elderly hypertensives and men with hypertension.
The overall percentage of adults with hypertension in Germany in 2008-2011 taking antihypertensives (72%; 95% CI 69-74) was similar to the percentage reported for USA (74%, 95% CI 72-76) but lower than that from Canada (80%, 95% CI 76-84) for a similar age range and period. 20 As in Table 1 [21] [22] [23] This could have contributed to the better control among adults with treated hypertension in Germany 2008-2011 (72%; 95% CI 69-74) compared to the 53% reported for the United States (95% CI 51-55), the 66% (95% CI 62-70) reported for Canada, and the 63% (95% CI 60-66) reported for England. 20, 23 Our finding of a better BP control among polytherapy compared to monotherapy users is in line with previous reports. 21, 23, 24 Furthermore, our estimated proportion of polytherapy users (67%) support the European Society of Hypertension/ the European Society of Cardiology Guidelines, 5 who mention that most patients require the combination of at least 2 drugs to achieve control.
The most commonly used antihypertensive class in 1998 was diuretics and beta-blockers in 2008-2011. In the United States diuretics remained the most common drug class over the 10-year period. 21 This is supported by the Joint National Committee of the US 25 who recommended in 2003, thiazidediuretics alone or in combination with other antihypertensive agent as first-line drugs for the management of hypertension. In Sweden 2006, both diuretics and beta-blockers were the most frequently used drugs for treating hypertension. 26 In Germany in this 10-year period the overall use of CCB went down and at the same time there was a shift in the CCB agent´s use, where amlodipine has increased (from 5% to 13%) whereas nifedipine decreased (from 10% to 0.5%). This shift was also reported in the United States 21, 27 and could be due to the different duration of effect (amlodipine has a longer acting effect). Additionally, the difference in side effects could also play a role as shown in a Chinese study, in which nifedipine had significantly more side effects than amlodipine. 28 Regarding antihypertensive agents, the most commonly used drug in Germany is metoprolol followed by ramipril, while in the United States it is lisinopril followed by metoprolol. In both countries the proportion of amlodipine use significantly increased over the 10-year period. In Germany 2011 as well as in the United States the most common polytherapy combination was ACE inhibitor plus thiazide-diuretic, while in England it was renin-angiotensin system blocker plus CCB. 21, 23 However, the different national approaches to manage hypertension make country comparisons difficult. The European Society of Hypertension/the European Society of Cardiology Guidelines, which are also recommended in Germany, 29 state that there is no evidence that different choices should be made based on age or gender (except for caution in using renin-angiotensin system-blockers in women with childbearing potential because of possible teratogenic effects). 5 In contrast, the British Guidelines recommend ACE inhibitors or a low-cost ARB in patients younger than 55 years and CCB in patients older than 55 years. 30 Similar to the United States, we found that women as well as older adults with hypertension are more likely to use antihypertensives. 21 This gender difference could be at least in part due to the fact that in Germany women go more often to the doctor than men, 31 and also they have higher hypertension awareness compared to men. 10 We have previously reported regional variations in antihypertensive use among men with hypertension. 32 For control, we expand on previous reports by analyzing control among treated and among all hypertensives. When controlling for treatment, regional differences in control are not significant any more. A further finding was that gender differences in BP control seem to be age-dependent. Of note, control among treated adults (DEGS1 18-79 years) was not significantly different in men and women (data not shown), as reported also from the United States. 21 However, when control was analyzed in 2 age groups for men and women, younger women had better control than younger men (and also than older women) even after adjusting for socio-demographic variables, health behavior indicators, comorbidities, and mono-vs. polytherapy. A potential explanation for this observed age-gender disparity in BP control could be the differential use of antihypertensive drug classes, which will be further studied.
Our finding that adults with hypertension and diabetes were more likely to use antihypertensive medications but less likely to have BP control than their respective reference group, was also observed in the United States and France. 21, 33 Moreover, Canada has reported that 54% of people with diabetes and hypertension have uncontrolled BP. 34 It is a known fact that alcohol drinking increases BP. 35 In our study, after adjusting for potential confounders high-risk alcohol drinking remained marginally associated with a poorer BP control, which was also in line with other studies. 36, 37 
Strengths and limitations
Strengths of our study include the large countrywide samples of noninstitutionalized adults in Germany, the highly standardized BP measurements, and the comprehensive medication data with ATC-coded medication based on medication packages and not recall. 38 However, one of our limitations is that severely ill and institutionalized persons could not participate in the surveys and those with generally low adherence to treatment might be underrepresented in a health survey, possibly leading to an overestimation of control rates. Furthermore, antihypertensive use and BP control depend on treatment adherence which cannot be directly analyzed with our data. Another point is that BP was measured on 1 single day as customary in epidemiological studies, while the diagnosis of hypertension and treatment decisions in clinical practice are based on elevated BP values on several occasions. High BP values may be lower on subsequent occasions due to a regression to the mean phenomenon. However this does not necessarily mean that we overestimate uncontrolled hypertension, since BP in epidemiological studies is resting BP after a defined and standardized resting time which is likely to be somewhat lower than casual BP taken in clinical practice. A further limitation is that BP and treatment were not differentiated by comorbidities. For control in participants with diabetes we have not used the lower BP target of <140/80 mm Hg recommended by the European Guidelines on cardiovascular disease Prevention. 2 However, even at the higher target of 140/90 mm Hg, only 67% of treated adults with hypertension and diabetes were controlled. Diabetes was positively associated with antihypertensive use but negatively associated with BP control. This is of concern as an adequate BP control in patients with diabetes significantly reduces the risk of macrovascular and microvascular complications.
Antihypertensive use and BP control among adults with hypertension in Germany have increased considerably. This increase is also linked to a change of the hypertension threshold from 160/95 to 140/90 mm Hg, in accordance with the latest guidelines on hypertension management, 39, 40 which coincided with the GNHIES98 survey but were most likely not yet largely implemented in clinical practice in 1998. However, even a decade later, there are still socio-demographic and health disparities in the treatment and control of hypertension and there is still a considerable prevention potential from both therapy and lifestyle changes. Targeting high-risk groups could help improving BP control and therefore reduce cardiovascular morbidity and mortality.
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